



## Zeposia® (ozanimod) – New indication

- On May 27, 2021, [Bristol Myers Squibb announced](#) the FDA approval of [Zeposia \(ozanimod\)](#), for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
- Zeposia is also approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Zeposia is the first sphingosine 1-phosphate (S1P) receptor modulator approved for patients with UC. Other drugs in the class (eg, [Gilenya® \[fingolimod\]](#)) are only approved for MS.
- The approval of Zeposia for the new indication was based on two randomized, double-blind, placebo-controlled studies [UC Study 1 (induction) and UC Study 2 (maintenance)] in adult patients with moderately to severely active UC. In UC Study 1, a total of 645 patients were randomized to either Zeposia or placebo for 10 weeks. The primary endpoint was clinical remission at week 10.
  - Clinical remission was achieved in 18% of patients receiving Zeposia vs. 6% of patients receiving placebo (treatment difference of 12, 95% CI: 8, 17;  $p < 0.0001$ ).
- In UC Study 2, a total of 457 patients who received Zeposia in either UC Study 1 or in an open-label arm and achieved clinical response at week 10 were re-randomized and were treated with either Zeposia or placebo for 42 weeks, for a total of 52 weeks of treatment. The primary endpoint was the proportion of patients in clinical remission at week 52.
  - Clinical remission was achieved in 37% of patients receiving Zeposia vs. 19% of patients receiving placebo (treatment difference of 19, 95% CI: 11, 26;  $p < 0.0001$ ).
- The most common adverse reactions ( $\geq 4\%$ ) with Zeposia use for UC were increased liver test, upper respiratory infection, and headache.
- The starting dosage for Zeposia for both of its indications is 0.23 mg once daily orally for days 1 to 4 and 0.46 mg once daily orally for days 5 to 7. After the initiation phase, the dosage should be increased to the maintenance dosage of 0.92 mg once daily orally.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.